NCT04963296
Stories
-
Hoffmann-La Roche posts results of Phase III obinutuzumab study in systemic lupus erythematosus
Results for the study were first posted on ClinicalTrials.gov on November 12, 2026. The Phase III trial enrolled 303 participants, with primary completion on September 15, 2025, and compared obinutuzumab to placebo in patients with active, autoantibody-positive systemic lupus erythematosus receiving standard-of-care therapy.